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Background
Uveitis occurs in 10%–15% of patients with JIA and is still
one of the most frequent causes of acquired blindness in
the developed world. Female sex, oligoarticular onset,
serum antinuclear antibodies (ANA) and early onset of
uveitis seem to increase the development of chronic uvei-
tis. If topical treatment fails, second-line agents may be
used, but not all patients respond. Infliximab has been
reported to be effective in some of these cases. This study
aims to assess the response and side effects associated with
infliximab in JIA patients with uveitis
Methods
Fourteen patients, (3 male and 11 female) aged from 6 to
26 years, were treated with infliximab between January
2005 and April 2008. Mean age at the beginning of ther-
apy was 9 years and 8 months.
All patients received also methotrexate (15 mg/mq
weekly). Infliximab was administered at 5 mg/kg dose at
0, 2, 4, 6 weeks and then every two months. Uveitis activ-
ity was evaluated as number of anterior chamber cells
every month.
Results
Infliximab was well tolerated and no immediate adverse
effects were recorded. Three patients achieved a complete
remission of uveitis for more than one year and stopped
anti-TNF treatment. Eight patients showed a good
response with improvement of inflammatory ocular activ-
ity and decreased episodes of uveitis. Those patients are
still on infliximab. Two patients were unresponsive to the
drug after one year.
Conclusion
In our experience infliximab was effective in 85% of
patients and none developed any serious systemic adverse
events attributable to infliximab.
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